A joint research project with Gifu University School of Medicine has been adopted by AMED\u2019s Practical Research for Intractable Disease program, accelerating preparation for a phase 1 clinical trial of Oremerumarin Alpha (HGF protein therapeutic). Non-clinical\/preclinical data gathering will be advanced, aiming to start clinical trials for the HGF therapeutic.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4884","jir_company_name":"Crinkle Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-01","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4884-20260901-01.pdf","jir_short_summary":"A joint research project with Gifu University School of Medicine has been adopted by AMED\u2019s Practical Research for Intractable Disease program, accelerating preparation for a phase 1 clinical trial of Oremerumarin Alpha (HGF protein therapeutic). Non-clinical\/preclinical data gathering will be advanced, aiming to start clinical trials for the HGF therapeutic.","jir_summary":"### Overview of business activities\nCrinkle Pharma is advancing a joint research project with the Gifu University Hospital to develop a novel treatment for idiopathic femoral head necrosis using HGF. This research project has been adopted for AMED\u2019s FY2026 Practical Research for Intractable Diseases (Second Call) and will advance to the phase of preparing for pharmaceutical clinical trials. The research and development lead is Prof. Haruhiko Akiyama of Gifu University, and the company, as a co-research institution, will accelerate the acquisition of non-clinical data required for trial implementation.\n\n### Outlook and impact\nData collection for initiating clinical trials and advancing preclinical studies are expected to enable an early start of clinical trials for the HGF treatment for idiopathic femoral head necrosis. The currently disclosed information is limited to the project title, development phase, project lead, and AMED adoption status; there is no disclosure of financial impact, specific funding use, or revenue figures.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#CrinklePharma, #IntractableDiseaseResearch, #HGFTherapeutic","jir_key_figures":"Project title: A physician-led clinical trial of a novel HGF therapeutic for idiopathic femoral head necrosis with high risk of femoral head collapse\nDevelopment phase: A-1 Pharmaceutical\u2019s trial preparation (Phase 1 steps)\nAdopted project: FY2026 intractable disease practical realization project (Second Call)","jir_meta_title":"Crinkle Pharma: HGF treatment co-developed with Gifu University adopted by AMED | Physician-led trial preparation accelerated","jir_meta_description":"Crinkle Pharma announces that its collaborative research with Gifu University School of Medicine has been adopted by AMED\u2019s Practical Research for Intractable Diseases. It will advance preclinical data collection for the HGF treatment and aim to commence clinical trials for idiopathic femoral head necrosis.","jir_og_title":"Crinkle Pharma AMED adoption accelerates HGF treatment clinical preparation","jir_og_description":"Joint research with Gifu University on the HGF treatment has been adopted by AMED. Accelerating the start of clinical trials through non-clinical data collection.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60827,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-109649","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n